Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Infection, Human Immunodeficiency Virus: early-phase trial registry
All 20 indexed Infection, Human Immunodeficiency Virus trials have closed enrollment; the archived set skews early-phase.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · none currently recruiting · #848 of 28,707 conditions by registered trial count
Infection, Human Immunodeficiency Virus: 20 US clinical trials tracked, none currently recruiting.
Infection, Human Immunodeficiency Virus is the subject of 20 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 3 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is ViiV Healthcare, running 15 of these trials.
Enrollment posture brief
Registry condition infection-human-immunodeficiency-virus
OPEN 0 | RECR 0% | LATE 3 | EARLY 17 | RANK #848 | SPON 15
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Infection, Human Immunodeficiency Virus has no open enrollment in this registry pull (20 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Infection, Human Immunodeficiency Virus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Infection, Human Immunodeficiency Virus is recruiting below its size-band peers.
0 of 20 indexed trials (0%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Infection, Human Immunodeficiency Virus research.
ViiV Healthcare accounts for 15 of 20 trials (75%). 2 distinct sponsors appear on at least one study for this condition label.
-
Most Infection, Human Immunodeficiency Virus trials plan to enrol fewer than 100 people.
Median target enrolment is 51 among the 20 trials that report a genuine target (sentinel values excluded). 15 of those (75%) plan for fewer than 100 participants.
-
Infection, Human Immunodeficiency Virus research is mostly interventional.
20 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
20 total, page 1 of 1
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ViiV Healthcare
NCT02951052
A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects
ViiV Healthcare
NCT00296504
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects
ViiV Healthcare
NCT01449929
Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
ViiV Healthcare
NCT01641809
Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine
ViiV Healthcare
NCT03078556
A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects
ViiV Healthcare
NCT02666053
Evaluation of the Bioequivalence of a Combined Formulated Tablet
ViiV Healthcare
NCT01622790
Single and Repeated Dose Escalation Study of GSK2838232
GlaxoSmithKline
NCT02795754
A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.
GlaxoSmithKline
NCT00386347
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
ViiV Healthcare
NCT00950859
Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction
ViiV Healthcare
NCT02027454
A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)
ViiV Healthcare
NCT02277600
Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations
ViiV Healthcare
NCT02738931
A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir
GlaxoSmithKline
NCT03234036
A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects
ViiV Healthcare
NCT02059031
A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761
ViiV Healthcare
NCT01031472
Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets
ViiV Healthcare
NCT01366547
Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers
ViiV Healthcare
NCT02185300
A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.
GlaxoSmithKline
NCT01138072
DDI Study of Etravirine and GSK1265744
GlaxoSmithKline
NCT00920296
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 2 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Infection, Human Immunodeficiency Virus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Infection, Human Immunodeficiency Virus trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Infection, Human Immunodeficiency Virus page
20 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Infection, Human Immunodeficiency Virus trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- ViiV Healthcare sponsors the most Infection, Human Immunodeficiency Virus trials on record, review their full trial history before evaluating a specific study. See ViiV Healthcare's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Infection, Human Immunodeficiency Virus condition card totals 20 registered trials; most-linked intervention abacavir 600 mg/lamivudine 300 mg; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.